The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand ...

Moderna (MRNA) stock gains as the company beats Q3 2025 forecasts despite lower COVID vaccine sales and narrows revenue ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand declines.

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

Moderna posted a smaller-than-expected quarterly loss and reduced its annual operating expenses outlook by $700 million on Thursday, helped by lower production costs and a cutback in research and ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...